A Study to Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers

Assisted Reproduction Clinical Trial

Official title:

Phase I Clinical Trial of Mass Balance of [14C]SHR7280 in Healthy Chinese Subjects

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06408948
• Other study ID #: SHR7280-106
• Status: Recruiting
• Phase: Phase 1
• Start date: June 7, 2024
• Est. completion date: June 30, 2024

Study information

• Verified date: June 2024
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: Ainan Zhou
• Phone: +86-135-8594-4968
• Email: ainan.zhou.az1[@]hengrui.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 8
• Est. completion date: June 30, 2024
• Est. primary completion date: June 20, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Sign the informed consent form prior to the trial and have a full understanding of the trial's procedures, content, and potential adverse reactions;

2. Healthy adult females and males between 18 and 45 years;

3. Body weight =50 kg(for male), body weight =45 kg(for female), and the body mass index (BMI) of 19 to 26 kg/m2;

4. From the signing of the informed consent form until 12 months after the last administration, the subject (including partner) has no family planning and is willing to use the high-efficiency contraceptive measures specified in the plan;

5. The first three menstrual cycles for women were regular, with a menstrual cycle of 21-35 days, and no abnormal uterine bleeding occurred.

Exclusion Criteria:

1. Comprehensive physical examination, vital signs, laboratory tests (blood routine, blood biochemistry, coagulation function, urine analysis, fecal routine+occult blood, thyroid function), full chest X-ray, 12 lead electrocardiogram, abdominal ultrasound, digital rectal examination, bilateral breast, uterus, and bilateral accessory ultrasound results that the researcher deems clinically significant;

2. Serum testosterone (T) <3.46 ng/mL during screening for male; serum follicle stimulating hormone (FSH) = 25mIU/mL during screening period for female;

3. Patients with QTcF>450 msec (male) and QTcF>470 msec (female) at the time of screening or baseline, or other clinically significant abnormalities determined by the researcher;

4. Hepatitis B surface antigen (HBsAg) positive, or anti hepatitis C virus (HCV) antibody positive, or human immunodeficiency virus (HIV) antigen/antibody combined test positive, or Treponema pallidum antibody positive;

5. Screening period or baseline period (D-1) serum pregnancy testing (serum ß- The HCG test )result is positive for female;

6. Women use the following contraceptive methods during screening visits:

sustained-release intrauterine devices, sustained-release contraceptives (subcutaneous implants, vaginal rings, microspheres, and microcapsules); Before screening, use long-acting contraceptive pills (using medroxyprogesterone acetate for 3 months and other injections for 1 month), oral contraceptives (such as short acting, long-acting, or emergency contraceptives) for 2 months before screening, and contraceptive patches for 1 month before screening; Special circumstances to be determined by the researcher;

7. Abuse of drugs or use of soft drugs (such as marijuana) in the three months prior to screening, or use of hard drugs (such as amphetamines, phencyclidine, etc.) in the year prior to screening; Or screening period urine drug test positive individuals, including: morphine, methamphetamine (methamphetamine), ketamine, ecstasy (methamphetamine), marijuana (tetrahydrocannabidiol acid);

8. Using any prescription, over-the-counter, herbal or dietary supplements before the first two screening weeks;

9. Women with a history of pregnancy, miscarriage, childbirth, or breastfeeding in the 6 months prior to screening;

10. Any clinical history of serious diseases or conditions that the researcher believes may affect the trial results, including but not limited to a history of circulatory, endocrine, nervous, digestive, urinary, or blood, immune, mental, and metabolic diseases;

11. Individuals with a history of malignant tumors or suspected to have sex hormone dependent malignant tumors;

12. Allergic constitution, or suspected allergy to any ingredient in SHR7280 formulation;

13. Individuals who have undergone any surgery in the first 3 months prior to screening, have not yet recovered after surgery, or are expected to have surgery or hospitalization plans during the trial period;

14. Perianal diseases with hemorrhoids or periodic/ongoing rectal bleeding; The subject is unable to swallow, or has a history of gastrointestinal dysfunction such as irritable bowel syndrome, inflammatory bowel disease, or has undergone surgery such as gastrectomy, which the researcher determines may affect drug absorption;

15. Habitual constipation or diarrhea;

16. Have a history of severe vomiting;

17. Individuals with a history of smoking in the first three months prior to screening (average daily smoking>5 cigarettes);

18. In the three months before screening, the average daily intake of alcohol exceeded 25 g (for example, 750 mL of beer, 250 mL of wine, or 50 mL of Baijiu); Or those with an alcohol breath test result of = 20 mg/dl during the screening period;

19. Habitually drinking grapefruit juice or excessive amounts of tea, coffee, and/or caffeinated beverages, or unable to quit during the trial period;

20. Select clinical trial participants who have participated in any other drug or medical device within the first 3 months or within 5 half-lives of the drug (depending on whether the drug is administered or the device is used);

21. Those who receive the vaccine within 2 weeks before the first administration or within 1 month after the last administration during the study period;

22. Individuals who have donated (or lost) blood and have donated (or lost) more than 400 mL of blood, or have received blood transfusions in the first 3 months prior to screening;

23. Engaged in workers who require long-term exposure to radioactive conditions; Or select individuals who have been significantly exposed to radiation (chest/abdominal CT = 2 times, or other types of X-ray examinations = 3 times) or have participated in radiopharmaceutical labeling trials in the one year prior to screening;

24. Difficulty swallowing, difficulty in venous blood collection, or physical condition unable to withstand blood collection; Or subjects who are expected to be unable to complete the entire trial follow-up;

25. According to the researcher's judgment, the subjects may have factors that affect drug absorption, distribution, metabolism, and excretion, or may reduce compliance, or other factors that are not suitable for participation in this study.

Related Conditions & MeSH terms

• Assisted Reproduction

Intervention

Drug:
• [14C]SHR7280
Patients will receive single dose of orally [14C]SHR7280 on Day 1.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Suzhou University	Suzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative recovery and recovery rate of total radioactive substance in urine and feces		0-240 hours
Primary	Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)		0-120 hours
Primary	Percentage of parent drug and its metabolites in urine and feces as a percentage of administered dose (%Dose)		0-240 hours
Primary	Radioactivity Tmax		0-120 hours
Primary	Radioactivity Cmax		0-120 hours
Primary	Radioactivity AUC		0-120 hours
Primary	Radioactivity t1/2		0-120 hours
Primary	Radioactivity CL/F		0-120 hours
Primary	Radioactivity Vz/F		0-120 hours
Primary	Total radioactivity ratio for blood/plasma		0-48 hours
Secondary	Plasma SHR7280: Tmax		0-120 hours
Secondary	Plasma SHR7280: Cmax		0-120 hours
Secondary	Plasma SHR7280: AUC		0-120 hours
Secondary	Plasma SHR7280: t1/2		0-120 hours
Secondary	Plasma SHR7280: CL/F		0-120 hours
Secondary	Plasma SHR7280: Vz/F		0-120 hours
Secondary	Plasma SHR7280: ?z		0-120 hours
Secondary	AEs and SAEs		Screening to 10 days